Denali Therapeutics (STU:4DN) Total Liabilities : €115.6 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Denali Therapeutics Total Liabilities?

Denali Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €115.6 Mil.

Denali Therapeutics's quarterly Total Liabilities increased from Sep. 2023 (€110.98 Mil) to Dec. 2023 (€112.76 Mil) and increased from Dec. 2023 (€112.76 Mil) to Mar. 2024 (€115.57 Mil).

Denali Therapeutics's annual Total Liabilities increased from Dec. 2021 (€391.06 Mil) to Dec. 2022 (€394.42 Mil) but then declined from Dec. 2022 (€394.42 Mil) to Dec. 2023 (€112.76 Mil).

Denali Therapeutics Total Liabilities Historical Data

The historical data trend for Denali Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Total Liabilities Chart

Denali Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

142.51

372.98

391.06

394.42

112.76

Denali Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															413.42	109.75	110.98	112.76	115.57

Denali Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Denali Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	71.509	+	(41.248	+	7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	112.8

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1058.142	-	945.385
	=	112.8

Denali Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	75.975	+	(39.591	+	0.00099999999999767
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	115.6

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1454.604	-	1339.037
	=	115.6

Denali Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Denali Therapeutics (STU:4DN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (STU:4DN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

DNLI:USA

Address

161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.denalitherapeutics.com

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Denali Therapeutics (STU:4DN) Headlines

No Headlines